Replies to post #307433 on Avid Bioservices Inc (CDMO)

[biopharm]

Peregrine shareholders should search this Medarex PDF file below and read carefully....just copy and paste and should be the first link/PDF file. The more I read thru it and discovered Bristol Myers Squibb NEVER made the offer directly but formed a holding company "Puma.." solely for the attempt to take over Medarex but read it carefully and I think this is one reason why Ronin wants to HALT research...we shall see

Albert Halegoua, et al. v. Medarex, Inc., et al. 09-CV-03824-Class Action Complaint For Violation ... - Securities Class Action Clearinghouse

[jbainseky]

Bio - what have you got with ties between team Ronin and Tappan Street Partners, LLC? I find it hard to believe there isn't a link somewhere.

FFTT

JBAIN

[biopharm]

Important all PPHM shareholders must read

Peregrine should learn from this Medarex sale and update their bylaws WITH this year's proxy vote and make sure the Poison Pill is enforced and kept in place


"
Goldman Sachs' Letter to MEDX Board of Directors (BOD) OPENLY Acknowledges that MEDX BOD Failed to Perform Its Fiduciary Responsibilities.... "

" "We [Goldman Sachs] were not requested to solicit, and did not solicit, interest from other parties with respect to an acquisition of or other business combination with the Company."

http://melanomamissionary.blogspot.com/2009/08/is-medarex-and-bristol-meyer-squibb-in.html?m=1

Is this what you want from Ronin Hedge Group to sell you out for breadcrumbs?? Hell no

I have wanted Ronin Hedge Group to file with SEC and TELL us all that this Medarex type disaster failure of fiduciary duty so would not happen if they want our votes and they fail to do so

Ronin Hedge Group fails to seek sealed court records in order to maximize shareholder value and they do not do so

Ronin Hedge Group can't even tell us the experts they have spoken to.....because likely they are tied it to a Medarex type deal which would possibly spoil their plans for a breadcrumbs deal

Ronin Hedge Group has failed big time but they can change....if they file with SEC and take care of these concerns ...we shall see

[biopharm]

"
Goldman Sachs' Letter to MEDX Board of Directors (BOD) OPENLY Acknowledges that MEDX BOD Failed to Perform Its Fiduciary Responsibilities.... "

" "We [Goldman Sachs] were not requested to solicit, and did not solicit, interest from other parties with respect to an acquisition of or other business combination with the Company."

http://melanomamissionary.blogspot.com/2009/08/is-medarex-and-bristol-meyer-squibb-in.html?m=1

Who is Peregrine's Goldman Sachs ? Who is in active discussions with a transfer or license or sale of IP ? Where is an investment bank ?

Are Fiduciary Duties being followed and adhered to ?

Maybe all BOD members at Peregrine should be aware of such Fiduciary Duties and how Medarex BOD failed in seeking competitive bids when they were seeking advise from Goldman Sachs.....

Goldman Sachs was covering their legal behinds as clearly seen above and would the change ....complete change of guards at BOD in Peregrine be possibly a way to transfer NO KNOWLEDGE BODs of the IP to vote and approve a license or some type of deal that makes them less guilty ?? ....or possibly entice them into long-term guarantee Avid revenue orders in exchange for signing off on a breadcrumbs deal ??

[biopharm]

Goldman Sachs' Letter to MEDX Board of Directors (BOD) OPENLY Acknowledges that MEDX BOD Failed to Perform Its Fiduciary Responsibilities.... "

" "We [Goldman Sachs] were not requested to solicit, and did not solicit, interest from other parties with respect to an acquisition of or other business combination with the Company."

http://melanomamissionary.blogspot.com/2009/08/is-medarex-and-bristol-meyer-squibb-in.html?m=1

It is NEVER too late to send cetified letters into all of Peregrine BODs and legal department ....because the fat lady has not even sung yet and the fat lady has not even appeared on stage yet it seems and you all think it was luck or chance BMS got Medarex for breadcrumbs? Maybe the same will be said for "x y or z" to have picked up Peregrine ...they just got lucky! I say hell no.....not luck, years and years of commercial like transmission waves being collaborated and finely tuned to send a clear, distorted message that Bavi has failed

Don't believe it....because Dr Jedd Wolchok cetainly is not believing it.

It is never too late till the fat lady sings and one must protect their investments to ensure the new Peregrine BODs minds have not been enticed into some new or old finely tuner, very clear, distorted message

With certified letters in their possessions we make them more legally bound to the laws of fiduciary Duties to Peregrine Pharmaceutical shareholders.

What type of competitive bidding is being utilized ? Has all new BODs been fully aware of all info made available to the old BODs and been given access to sealed court records that show possibly how Peregrine IP has been a success

We are now into combinations and Sunrise Bavi arm patients would be considered the 1st vital Part of a combination ....as FDA SOC treatment (after Sunrise halt ) was the next part of the combination, so how is it if MOS not met yet with those patients we are not hearing the fat lady sing ??

(Unless she needs a Sard Verbinnen prepared stage...)

....
.....
Bristol’s $2.4 billion purchase of Medarex — which pharmaceutical analysts routinely cite as one of the best acquisitions in the history of the industry — would give the company not only a new blockbuster but also a leadership position in a burgeoning drug category: immuno-oncology.

Luck had something to do with it. But Bristol’s top management had helped manufacture that luck by recognizing — when many others didn’t — that Yervoy was a diamond in the rough.

In 2000, Medarex began its first phase of human testing on its new “CTLA-4-blockade” — in patients who had either prostate cancer or metastatic melanoma, a deadly form of skin cancer. If anything, though, the clinical trials provoked more questions (and even doubt) than answers. “The response pattern was a little bit funky,” says Francis Cuss, Bristol’s chief science officer. “People were getting benefits, but not according to conventional wisdom.”

When Jedd Wolchok, a cancer doctor and immunologist leading a Yervoy trial at Memorial Sloan Kettering, examined a melanoma patient’s scan 12 weeks after he’d received his course of treatment, the results were utterly disappointing — just like those of any other metastatic patient in the final throes of the disease: The tumors had gotten bigger, and there were more of them. “It looked for all the world as if the drug was failing,” says Wolchok. But before he could deliver the news, his patient stopped him: “Don’t tell me what the pictures show,” he said. “I first want to tell you I feel better.”
...
...
https://www.google.com/amp/amp.timeinc.net/fortune/2014/06/02/fortune-500-bristol-myers